Loading company…
PromiseBio uses AI to analyze protein modifications for precision medicine in autoimmune diseases.
PromiseBio develops a cloud-based AI platform that analyzes post-translational modifications in proteins to study autoimmune diseases and identify biomarkers. Its tools are aimed at biopharmaceutical companies involved in drug development and clinical trials. Founded in 2023, the company is based in Tel Aviv, Israel. In December 2024, it received an undisclosed grant from the Israel Innovation Authority.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in